H.C. Wainwright lowered the firm’s price target on Anavex (AVXL) to $20 from $42 and keeps a Buy rating on the shares after blarcamesine received a negative trend opinion from European regulators. The firm cites the reduced probability of approval for blarcamesine in Europe for treatment of Alzheimer’s disease for the target cut.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL: